Flextronics Intl (FLEX) Partners with Ichor, Synthetic Biologics
Post# of 70
Posted On: 05/08/2014 9:33:49 AM
Brokerage firm Argus has upgraded Flextronics International Ltd. (FLEX) from Hold to Buy with a price target of $13.00 per share.
FLEX reported that its Medical Group will provide design and manufacturing services to Ichor Medical Systems for the development of its next generation TriGrid(TM) DNA Delivery System, an electroporation device used to deliver DNA vaccines and treatments addressing a broad spectrum of disease indications. The TriGrid technology has recently been licensed by Pfizer for the intracellular delivery of their DNA-based cancer vaccines.
FLEX engineers will work with Ichor staff to develop and build the electronic and mechanical components of the device.
According to its guidance for the first quarter ending June 27, 2014, FLEX expects revenue to be in the range of $6.0 to $6.5 billion and adjusted EPS is expected to be in the range of $0.20 to $0.24 per diluted share.
FLEX is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories.
More about Flextronics International Ltd. (FLEX) at www.flextronics.com
**
A social networking service is a platform to build social networks or social relations among people who, share interests, activities, backgrounds or real-life connections.
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.
The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 526th community website in the U.S., associated with 2090 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com
**
Synthetic Biologics Inc. (SYN) announced that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. SYN's extensive C. diff patent estate now includes over 25 U.S. and international patents.
The recent European patents EP1451292 and EP2038411 were validated in 16 major European nations and provide composition of matter coverage for strains that allow production of SYN's proprietary oral enzymes and potential further candidate oral enzymes, respectively. In addition, allowed Australian Patent Application 2011257092 contains claims to compositions and methods of using the SYN's lead C. diff candidate, SYN-004.
C. diff infections are a leading cause of hospital acquired infections that generally occur secondary to treatment with IV antibiotics, which are administered to approximately 14.4 million patients in the United States annually.
SYN is in preclinical development of SYN-004, a novel second generation oral enzyme drug candidate, for co-administration with commonly used intravenous (IV) antibiotics intended to protect the gastrointestinal microflora (microbiome) from the effects of IV antibiotics for the prevention of C. diff infections.
SYN is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases.
More about Synthetic Biologics Inc. (SYN) at www.syntheticbiologics.com.
**
For the first quarter 2014, Omega Protein Corporation (OME) posted revenues of $63.5 million, a 30% increase year over year, net income of $8.0 million, or $9.0 million excluding plant closure charges and loss on disposal of assets for the quarter, compared to $2.8 million, or $3.1 million excluding the loss on disposal of assets, in the same period a year ago, and earnings per diluted share of $0.37, or $0.42 excluding plant closure charges and loss on disposal of assets for the period, compared to $0.14, or $0.15 excluding the loss on disposal of assets, in the first quarter 2013
OME is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.
More about Omega Protein Corporation (OME) at www.omegaprotein.com.
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
FLEX reported that its Medical Group will provide design and manufacturing services to Ichor Medical Systems for the development of its next generation TriGrid(TM) DNA Delivery System, an electroporation device used to deliver DNA vaccines and treatments addressing a broad spectrum of disease indications. The TriGrid technology has recently been licensed by Pfizer for the intracellular delivery of their DNA-based cancer vaccines.
FLEX engineers will work with Ichor staff to develop and build the electronic and mechanical components of the device.
According to its guidance for the first quarter ending June 27, 2014, FLEX expects revenue to be in the range of $6.0 to $6.5 billion and adjusted EPS is expected to be in the range of $0.20 to $0.24 per diluted share.
FLEX is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories.
More about Flextronics International Ltd. (FLEX) at www.flextronics.com
**
A social networking service is a platform to build social networks or social relations among people who, share interests, activities, backgrounds or real-life connections.
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.
The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 526th community website in the U.S., associated with 2090 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com
**
Synthetic Biologics Inc. (SYN) announced that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. SYN's extensive C. diff patent estate now includes over 25 U.S. and international patents.
The recent European patents EP1451292 and EP2038411 were validated in 16 major European nations and provide composition of matter coverage for strains that allow production of SYN's proprietary oral enzymes and potential further candidate oral enzymes, respectively. In addition, allowed Australian Patent Application 2011257092 contains claims to compositions and methods of using the SYN's lead C. diff candidate, SYN-004.
C. diff infections are a leading cause of hospital acquired infections that generally occur secondary to treatment with IV antibiotics, which are administered to approximately 14.4 million patients in the United States annually.
SYN is in preclinical development of SYN-004, a novel second generation oral enzyme drug candidate, for co-administration with commonly used intravenous (IV) antibiotics intended to protect the gastrointestinal microflora (microbiome) from the effects of IV antibiotics for the prevention of C. diff infections.
SYN is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases.
More about Synthetic Biologics Inc. (SYN) at www.syntheticbiologics.com.
**
For the first quarter 2014, Omega Protein Corporation (OME) posted revenues of $63.5 million, a 30% increase year over year, net income of $8.0 million, or $9.0 million excluding plant closure charges and loss on disposal of assets for the quarter, compared to $2.8 million, or $3.1 million excluding the loss on disposal of assets, in the same period a year ago, and earnings per diluted share of $0.37, or $0.42 excluding plant closure charges and loss on disposal of assets for the period, compared to $0.14, or $0.15 excluding the loss on disposal of assets, in the first quarter 2013
OME is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.
More about Omega Protein Corporation (OME) at www.omegaprotein.com.
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
(0)
(0)